{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:23:50Z","timestamp":1791559430973,"version":"4.3.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"DOI":"10.7759\/cureus.115106","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:51:25Z","timestamp":1787601085000},"source":"Crossref","is-referenced-by-count":1,"title":["A Case of Dual Endocrinopathies Induced by Pembrolizumab Following Treatment for Non-small Cell Lung Cancer: Type 1 Diabetes and Hyperthyroidism\/Autoimmune Thyroiditis"],"prefix":"10.7759","author":[{"given":"Carolina","family":"Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Ansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihunanya","family":"Agomuoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanika","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geetha","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Taha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Merck. Merck receives FDA Breakthrough Therapy Designation for KEYTRUDA\u00ae (pembrolizumab) in advanced non-small cell lung cancer. (2014). Accessed. April 29, 2026: https:\/\/www.merck.com\/news\/merck-receives-fda-breakthrough-therapy-designation-for-keytruda-pembrolizumab-in-advanced...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2021-003038","article-title":"Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer","volume":"31","author":"Valencia Soto CM","year":"2023","unstructured":"Valencia Soto CM, Villaca\u00f1as Palomares MV, Garcia-Avello Fern\u00e1ndez-Cueto A, et al.. Predictive value of immune-related adverse events during pembrolizumab treatment in non-small cell lung cancer. Eur J Hosp Pharm. 2023, 31:40-5. 10.1136\/ejhpharm-2021-003038","journal-title":"Eur J Hosp Pharm"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2302983","article-title":"Perioperative pembrolizumab for early-stage non-small-cell lung cancer","volume":"389","author":"Wakelee H","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, et al.. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023, 389:491-503. 10.1056\/NEJMoa2302983","journal-title":"N Engl J Med"},{"key":"ref4","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han Y","year":"2020","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020, 10:727-42.","journal-title":"Am J Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx076","article-title":"Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic","volume":"28","author":"Kang SP","year":"2017","unstructured":"Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MAB, Rubin EH. Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic. Ann Oncol. 2017, 28:1388-98. 10.1093\/annonc\/mdx076","journal-title":"Ann Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.568931","article-title":"The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment","volume":"11","author":"Hudson K","year":"2020","unstructured":"Hudson K, Cross N, Jordan-Mahy N, Leyland R. The extrinsic and intrinsic roles of PD-L1 and its receptor PD-1: implications for immunotherapy treatment. Front Immunol. 2020, 11:568931. 10.3389\/fimmu.2020.568931","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2016.1199310","article-title":"Pembrolizumab (Keytruda)","volume":"12","author":"Kwok G","year":"2016","unstructured":"Kwok G, Yau TC, Chiu JW, Tse E, Kwong YL. Pembrolizumab (Keytruda). Hum Vaccin Immunother. 2016, 12:2777-89. 10.1080\/21645515.2016.1199310","journal-title":"Hum Vaccin Immunother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok TSK","year":"2019","unstructured":"Mok TSK, Wu YL, Kudaba I, et al.. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019, 393:1819-30. 10.1016\/S0140-6736(18)32409-7","journal-title":"Lancet"},{"key":"ref9","unstructured":"Side effects in clinical trials. Accessed. April 29, 2026: https:\/\/dipg.org\/treatment\/clinical-trials\/side-effects\/."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely JR Jr","year":"2021","unstructured":"Patrinely JR Jr, Johnson R, Lawless AR, et al.. Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncol. 2021, 7:744-8. 10.1001\/jamaoncol.2021.0051","journal-title":"JAMA Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.8836","article-title":"Pembrolizumab: an immunotherapeutic agent causing endocrinopathies","volume":"12","author":"Chaudry A","year":"2020","unstructured":"Chaudry A, Chaudry M, Aslam J. Pembrolizumab: an immunotherapeutic agent causing endocrinopathies. Cureus. 2020, 12:e8836. 10.7759\/cureus.8836","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0713-y","article-title":"Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature","volume":"7","author":"Gunjur A","year":"2019","unstructured":"Gunjur A, Klein O, Kee D, Cebon J. Anti-programmed cell death protein 1 (anti-PD1) immunotherapy induced autoimmune polyendocrine syndrome type II (APS-2): a case report and review of the literature. J Immunother Cancer. 2019, 7:241. 10.1186\/s40425-019-0713-y","journal-title":"J Immunother Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"de Filette JM","year":"2019","unstructured":"de Filette JM, Pen JJ, Decoster L, et al.. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019, 181:363-74. 10.1530\/EJE-19-0291","journal-title":"Eur J Endocrinol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas M","year":"2018","unstructured":"Rojas M, Restrepo-Jim\u00e9nez P, Monsalve DM, et al.. Molecular mimicry and autoimmunity. J Autoimmun. 2018, 95:100-23. 10.1016\/j.jaut.2018.10.012","journal-title":"J Autoimmun"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.14341\/probl12698","article-title":"Development of destructive thyroiditis and diabetes mellitus after three injections of pembrolizumab for skin melanoma. (Article in Russian)","volume":"67","author":"Glibka AA","year":"2021","unstructured":"Glibka AA, Mel Nichenko GA, Mikhina MS, Mazurina NV, Kharkevich GY. Development of destructive thyroiditis and diabetes mellitus after three injections of pembrolizumab for skin melanoma. (Article in Russian). Probl Endokrinol (Mosk). 2021, 67:20-7. 10.14341\/probl12698","journal-title":"Probl Endokrinol (Mosk)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35276","article-title":"A case of pembrolizumab-induced diabetic ketoacidosis and hyperthyroidism in a patient with recurrent esophageal adenocarcinoma","volume":"15","author":"Salangsang J","year":"2023","unstructured":"Salangsang J, Sapkota S, Kharel S, Gupta P, Kalla A. A case of pembrolizumab-induced diabetic ketoacidosis and hyperthyroidism in a patient with recurrent esophageal adenocarcinoma. Cureus. 2023, 15:e35276. 10.7759\/cureus.35276","journal-title":"Cureus"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/468079-a-case-of-dual-endocrinopathies-induced-by-pembrolizumab-following-treatment-for-non-small-cell-lung-cancer-type-1-diabetes-and-hyperthyroidismautoimmune-thyroiditis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T19:51:26Z","timestamp":1787601086000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/468079-a-case-of-dual-endocrinopathies-induced-by-pembrolizumab-following-treatment-for-non-small-cell-lung-cancer-type-1-diabetes-and-hyperthyroidismautoimmune-thyroiditis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.115106","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}